拉丁美洲制药行业市场前景及投资研究报告-外文版培训课件2024.7temu

POLITICS

&

SOCIETYPharmaceuticalindustryinLatinAmericaCHAPTER

01GlobaloverviewRevenueoftheworldwidepharmaceuticalmarketfrom2001to2023(inbillionU.S.dollars)Pharmaceuticalmarket:worldwiderevenue2001-20231,8001,6001,4001,2001,0001,6071,4821,4501,3121,2781,2141,1351,1161,064

1,073994963

96488883179980072664960156060040020004984283902001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

20234/statistics/263102/pharmaceutical-market-worldwide-revenue-since-2001Theglobalpharmaceuticalmarkethasexperiencedsignificantgrowthinrecentyears.For2023,thetotalglobalpharmaceuticalmarketwasestimatedataround1.6trillionU.S.dollars.Thisisanincreaseofover100billiondollarscomparedto2022.

ReadmoreNote(s):WorldwideSource(s):IQVIALeadingpharmaceuticalproductsbysalesworldwidein2023(inbillionU.S.dollars)Toppharmaceuticalproductsbysalesworldwide2023SalesinbillionU.S.dollars100Keytruda(Merck&Co.)Comirnaty(BioNTech/Pfizer)*Humira(AbbVie)5152025253015.314.413.9Ozempic(NovoNordisk)Eylea(Bayer/Regeneron)Eliquis(BMS)12.912.211.911.610.9Biktarvy(Gilead)Dupixent(Sanofi/Regeneron)Stelara(J&J)Darzalex(J&J)9.75Description:Unlikeinthetwoyearsbefore,COVID-19vaccineComirnatydidnotmaintainitsplaceastheglobaltoprankedpharmaceuticalproductbasedonrevenue.Merck'scancerdrugKeytrudaisthenewbest-sellingdrugworldwide,withsome25billionU.S.dollarsofrevenue.Humiracameinasthirdrankeddrugin2023,withrevenuestotaling14.4billiondollars.ReadmoreNote(s):Worldwide;*Pfizer'ssaleswere11.2billionUSDandBioNTech’swereabout4.1billionUSD.ReadmoreSource(s):Varioussources(companydata);Website()Revenuesofleading10nationalpharmaceuticalmarketsworldwidein2022(inbillionU.S.dollars)Revenuesoftop10globalpharmaceuticalmarkets2022RevenueinbillionU.S.dollars3000100200400500600700UnitedStatesChina*631.5112.6Japan67.259.5GermanyFrance41.836.1ItalyUnitedKingdomCanada33.429.428.528.2SpainBrazil**6Description:In2022,therevenueoftheChinesepharmaceuticalmarkettotaledapproximately113billionU.S.dollars.Thisstatisticshowstherevenuesofthetop10nationalpharmaceuticalmarketsworldwidein2022.TheUnitedStatesremainsbyfarthelargestmarketforpharmaceuticalproducts,generatingmorerevenuethanallothercountriesfromthetop10listcombined.ReadmoreNote(s):WorldwideSource(s):IQVIAPharmaceuticalmarketforecastfor2027,byworldregion(inbillionU.S.dollars)Pharmaceuticalmarketforecast2027,byworldregionSpendinginbillionU.S.dollarsMaximum355Minimum4000100200180300500600700800790900820NorthAmericaWesternEuropeChina385210140138LatinAmericaAsia-Pacific110108120EasternEuropeJapan100917174AfricaandMiddleEastIndia5439357Description:NorthAmericaisprojectedtostaybyfarthelargestregionalpharmaceuticalmarketin2027,withanestimatedmedicinespendingbetween790and820billionU.S.dollars.Chinaestablisheditselfasthesecond-largestnationalmarket,behindtheUnitedStates.ReadmoreNote(s):UnitedStates;asofNovember2022Source(s):IQVIAPharmaceuticalmarketCAGRforecastfor2023-2027,byworldregionPharmaceuticalmarketCAGRforecast2023-2027,byworldregionCompoundannualgrowthrate2023-2027Maximum2%Minimum4%-4%-2%0%6%8%10%12%10.5%IndiaLatinAmericaEasternEuropeAsia-Pacific7.5%10%7%9%8.5%6%5.5%7.5%AfricaandMiddleEastWesternEuropeNorthAmericaChina4.5%6.5%3.5%5.5%2.5%5%2%1%Japan-2%8Description:IndiaandLatinAmericaareprojectedtobetheregionalpharmaceuticalmarketswiththehighestgrowthratesintheperiodfrom2023to2027,atroughlybetweensevenand11percent.OtherregionalmarketswithprojectedhighergrowthratesareEasternEurope,Asia-Pacific,andAfricaincludingtheMiddleEast.ReadmoreNote(s):UnitedStates;asofNovember2022Source(s):IQVIAMarketvalueofpharmaceuticalsinselectedcountriesandregionsinLatinAmericain2021(inbillionU.S.dollars)PharmamarketvalueinLatinAmerica2021,bycountryMarketvalueinbillionU.S.dollars1005152025BrazilMexico22.818.51Argentina6.03CentralAmericaChile2.522.051.751.7ColombiaEcuadorPeru1.060.61DominicanRepublicParaguay0.480.36Uruguay9Description:In2021,BrazilwasbyfartheLatinAmericancountrywiththehighestpharmaceuticalmarketvalue,amountingtoaround22.81billionU.S.dollars.Mexicorankedsecond,withapharmamarketvalueofapproximately8.51billionU.S.dollars.Asawhole,LatinAmericaaccountedforabout3.7percentoftheglobal2021pharmaceuticalmarketrevenue.ReadmoreNote(s):LAC;2021;marketvalueatex-factorypriceSource(s):CILFA;IQVIACHAPTER

02ForeigntradeValueofpharmaceuticalexportsfromLatinAmericaandtheCaribbeanfrom2018to2023(inbillionU.S.dollars)PharmaceuticalexportsfromLatinAmericaandtheCaribbeanfrom2018-2023109.29998.18.028765432107.477.2520182019202020212022202311Description:In2023,thecombinedvalueofpharmaceuticalexportsfromLatinAmericaandtheCaribbeanwasapproximately9.3billionU.S.dollars.Thismarksthehighestlevelofpharmaceuticalexportsfromtheregionobservedduringtheperiodanalyzed.In2022,thecountrywiththehighestvalueofpharmaceuticalexportsinLatinAmericawasMexico.ReadmoreNote(s):LAC;2018to2023Source(s):InternationalTradeCentre;TradeMap;UNComtradeValueofpharmaceuticalimportsintoLatinAmericaandtheCaribbeanfrom2018to2023(inbillionU.S.dollars)PharmaceuticalimportsinLatinAmerica&theCaribbean2018-202345403538.9638.4737.323025201510527.7527.7827.37020182019202020212022202312Description:ThehighestvalueofpharmaceuticalproductimportsintoLatinAmericaandtheCaribbeanwasrecordedin2023,withapproximately39billionU.S.dollars.Thevalueofpharmaceuticalimportsacrossthisselectedgroupofcountriesincreasedbyover10billionU.S.dollarscomparedto2020,whenitreached27.6billionU.S.dollars.In2022,BrazilwastheLatinAmericancountrywiththehighestvalueofꢀpharmaceuticalimportsꢀintheregion.ReadmoreNote(s):LAC;2018to2023Source(s):InternationalTradeCentre;TradeMap;UNComtradeLeadingcountriesofdestinationofpharmaceuticalproductsexportedfromLatinAmericaandtheCaribbeanin2023(inmillionU.S.dollars)PharmaceuticalexportsinLatinAmericaandtheCaribbeanin2023,bycountryValueinmillionU.S.dollars02004006008001,0001,2001,4001,6001,800UnitedStatesCostaRicaHondurasGuatemalaEcuador1,655.62598.23512.88505.52497.96Panama436.2113Description:In2023,theUnitedStatesstoodastheleadingdestinationforpharmaceuticalexportsfromLatinAmericaandCaribbeancountries,reachingover1.6billionU.S.dollars.CostaRicaandHondurasfollowed,witharound598and513millionU.S.dollars'worthofpharmaceuticals,respectively.Overall,pharmaceuticalexportsfromLatinAmericaandtheCaribbeantotaledabout9.3billionU.S.dollarsin2023.ReadmoreNote(s):LAC;2023;*Figurewascalculatedbybasedonthevaluesbycountryprovidedbythesource.

ꢀThesourcedoesnotprovideanexactdateofpublication.Thereleasedatecorrespondstothedateofconsultation.

ꢀFigureshave[...]

ReadmoreSource(s):InternationalTradeCentre;TradeMap;UNComtradeLeadingcountriesoforiginofpharmaceuticalproductsimportedintoLatinAmericaandtheCaribbeanin2023(inbillionU.S.dollars)CountriesoforiginofpharmaceuticalimportsLatinAmericaandtheCaribbean2023ImportsinbillionU.S.dollars01234567UnitedStatesGermanySwitzerlandBelgium6.485.062.452.19Ireland2.0614Description:In2023,theUnitedStateswastheleadingcountryoforiginofpharmaceuticalimportsintoLatinAmericaandtheCaribbean,totalingaround6.5billionU.S.dollars.GermanyandSwitzerlandfollowed,withapproximatelyfiveand2.5billionU.S.dollars,respectively.Together,thesethreecountriesaccountedfor36percentoftheLatinAmericaandtheCaribbean'spharmaceuticalimportsin2023.ReadmoreNote(s):LAC;2023Source(s):InternationalTradeCentre;TradeMap;UNComtradeTradebalanceofpharmaceuticalproductsinLatinAmericaandtheCaribbeanfrom2018to2023(inbillionU.S.dollars)TradebalanceofpharmaproductsinLatinAmericaandtheCaribbean2018-20230-5-10-15-20-19.76-20.192019-20.442020-25-30-35-28.362022-29.682023-30.822021201815Description:In2023,LatinAmericaandtheCaribbeanhadatradedeficitinpharmaceuticalproducts,withpharmaceuticalimportssurpassingexportsbyapproximately29.5billionU.S.dollars.Thisdeficitmarkedthesecond-largesttradegapintheregion.Theonlyyearthatexceededthisdeficitwas2021,whereimportsexceededexportsbyaround30billionU.S.dollars,representingthelargestdeficitobservedduringthedepictedperiod.

ReadmoreNote(s):LAC;2018to2023Source(s):InternationalTradeCentre;TradeMap;UNComtradeTradebalanceofpharmaceuticalproductsinLatinAmericaandtheCaribbeanin2023,bysegment(inbillionU.S.dollars)PharmaceuticaltradebalanceininLatinAmericaandtheCaribbean2023,bysegmentTradebalanceinmillionU.S.dollars-18,000

-16,000

-14,000

-12,000

-10,000

-8,000

-6,000

-4,000

-2,0000MedicamentsconsistingofmixedorunmixedproductsfortherapeuticorprophylacticusesHumanblood;animalbloodpreparedfortherapeutic,prophylacticordiagnosticusesWadding,gauze,bandagesandthelikeMedicamentsconsistingoftwoormoreconstituentsDriedglandsandotherorgansfororgano-therapeuticuses.Otherpharmaceuticalpreparationsandproducts16Description:In2023,thelargestꢀdeficitsinthepharmaceuticaltradebalanceofLatinAmericaandtheCaribbeanwereobservedinimportsofmedicamentconsistingofproductsfortherapeutic,orprophylacticuses,andbloodpreparedfortherapeutic,prophylactic,ordiagnosticuses.Theseimportsamountedtoapproximately17and12billiondollars,respectively.ReadmoreNote(s):LAC;2023Source(s):InternationalTradeCentre;TradeMap;UNComtradeCHAPTER

03KeysegmentsRevenueofthepharmaceuticalsmarketinLatinAmericafrom2016to2028(inbillionU.S.dollars)RevenueofpharmaceuticalsinLatinAmerica2016-202860504056.0952.4949.1246.344.0641.8241.4341.4736.1433.5732.5632.4331.813020100201620172018201920202021202220232024202520262027202818Description:TherevenueofthepharmaceuticalsmarketinLatinAmericawasforecasttocontinuouslyincreasebetween2024and2028byintotal12billionU.S.dollars(+27.24percent).Afterthesixthconsecutiveincreasingyear,theindicatorisestimatedtoreach56.09billionU.S.dollarsandthereforeanewpeakin2028.ReadmoreNote(s):Source(s):RevenueofthevaccinesmarketinLatinAmericafrom2016to2028(inbillionU.S.dollars)RevenueofvaccinesinLatinAmerica2016-2028987654328.475.693.283.23.032.982.812.761.31.271.211.221.110201620172018201920202021202220232024202520262027202819Description:TherevenueofthevaccinessegmentofthepharmaceuticalsmarketinLatinAmericawasforecasttocontinuouslyincreasebetween2024and2028byintotal0.2billionU.S.dollars(+6.6percent).Accordingtothisforecast,in2028,theindicatorwillhaveincreasedforthethirdconsecutiveyearto3.2billionU.S.dollars.ReadmoreNote(s):Source(s):RevenueoftheoncologydrugsmarketinLatinAmericafrom2016to2028(inbillionU.S.dollars)RevenueofoncologydrugsinLatinAmerica2016-202816141210814.112.3610.829.498.347.296.346.295.5265.124.984.873.89420201620172018201920202021202220232024202520262027202820Description:TherevenueoftheoncologydrugssegmentofthepharmaceuticalsmarketinLatinAmericawasforecasttocontinuouslyincreasebetween2024and2028byintotal5.8billionU.S.dollars(+69.54percent).Afterthesixthconsecutiveincreasingyear,theindicatorisestimatedtoreach14.1billionU.S.dollarsandthereforeanewpeakin2028.ReadmoreNote(s):Source(s):Valueoftheover-the-counter(OTC)pharmaceuticalsmarketinLatinAmericafrom2022to2027(inbillionU.S.dollars)OTCdrugsmarketvalueinLatinAmerica2022-202720181617.31614.713.5141210812.411.5642020222023202420252026202721Description:Themarketvalueofover-the-counter(OTC)pharmaceuticalsinLatinAmericaisforecastedtoreachover17billionU.S.dollarsby2027,upfromanestimatedvalueof11.5billionU.S.dollarsin2022.In2021,theOTCpharmaceuticalmarketrevenueinBrazilamountedtoover4.5billionU.S.dollars.ReadmoreNote(s):LAC;2022Source(s):MarketDataForecast;RevenueoftheOTCpharmaceuticalsmarketinLatinAmericain2022RevenueoftheOTCpharmaceuticalsmarketinLatinAmerica2022Marketrevenuein$0500,000,0001,000,000,0001,500,000,0002,000,000,0002,500,000,0003,000,000,000AnalgesicsCold&CoughRemediesDigestives&IntestinalRemediesVitamins&Minerals2,781,495,071.49$2,252,801,355.81$1,898,276,501.38$1,864,269,928.93$SkinTreatment1,501,699,001.26$22Description:Concerningthefiveselectedsegments,thesegmentAnalgesicshasthelargestrevenuewith2,781,495,071.49U.S.dollars.Contrastingly,SkinTreatmentisrankedlast,with1,501,699,001.26U.S.dollars.Theirdifference,comparedtoAnalgesics,liesat1,279,796,070.23U.S.dollars.ReadmoreNote(s):Jan1sttoDec31st2022Source(s):Over-the-counter(OTC)pharmaceuticalse-commercerevenueinLatinAmericafrom2018to2029,bysegment(inmillionU.S.dollars)OTCpharmaceuticalse-commercerevenueinLatinAmerica2018-2029,bysegmentIncontinenceAnalgesicsCold&CoughRemediesDigestives&IntestinalRemedies

Vitamins&MineralsSkinTreatmentHandSanitizer7,0006,0005,0004,0003,0002,0001,000020182019202020212022202320242025202620272028202923Description:Overthelasttwoobservations,therevenueisforecasttosignificantlyincreaseinallsegments.EspeciallynotableistheremarkablyrobustgrowthobservedintheIncontinencesegmentasweapproachtheendoftheforecastperiod.Thisvalue,reaching142.4millionU.S.dollars,standsoutsignificantlycomparedtotheaveragechanges,whichareestimatedat44.7714millionU.S.dollars.ReadmoreNote(s):LAC;2018to2029;estimatesSource(s):CHAPTER

04MainplayersRankingofmainpharmaceuticalandpharmaceuticalretailcompaniesoutof500leadingcompaniesinLatinAmericaasof2023RankingofmainpharmaceuticalcompaniesamongleadingfirmsinLatinAmerica2023Leading

pharmaceutical

and

pharmaceutical

retail

companiesRaiaDrogasil(Brazil)Ranking79ProfarmaDistribuidoradeProductosFarmacéuticos(Brazil)HyperaPharma(Brazil)236239GenommaLabInternacional(Mexico)FarmaciasBenavides(Mexico)332341ProcapsGroup(Colombia)46225Description:ThreeBrazilian,threeMexican,andoneColombiancompanywithinthecategoryofpharmaceuticalandpharmaceuticalretailfirmsrankedamongtheleading500companiesinLatinAmericabasedonrevenue.RaiaDrogasil,adrugstorecompanyheadquarteredinSãoPaulo,hadthehighestrevenuewithinthiscategory,ranking79amongthe500.ꢀAlsobasedinSãoPaulo,HyperaPharmaisconsideredtheleadingpharmaceuticalcompanyintheregionaccordingtotheranking,followedby[...]

ReadmoreNote(s):CentralandSouthAmericaSource(s):AméricaEconomíaLeadinghealthandpharmaretailersinLatinAmericabasedonestimatedsalesin2021and2026(inbillionU.S.dollars)LeadinghealthandpharmaretailersinLatinAmericabasedonsales2021-20262021202665432105.54.43.53.22.72.2RaiaDrogasilFarmaciasGuadalajaraOxxo26Description:Accordingtotheestimatedsalesfigures,RaiaDrogasilwastheleadinghealthandpharmaretailerinLatinAmericain2021,withthreeandahalfbillionU.S.dollars.FarmaciasGuadalajaraandOxxocameinsecondandthirdintheranking,withestimatedsalesof3.2billionU.S.dollarsand2.2billionU.S.dollars,respectively.Forecastsshowthattherankingisexpectedtolooksimilarin2026,wherethesalesofRaiaDrogasilwillreachtoaboutfiveandahalfbillionU.S.dollars.

ReadmoreNote(s):LAC;September2021Source(s):EdgebyAscentialLeadingcompaniesinthepharmaceuticalandcosmeticssectorinBrazilin2022,basedonnetrevenue(inbillionBrazilianreals)Brazil:majorpharmaceutical&cosmeticscompanies2022,byrevenueNetrevenueinbillionBrazilianreals0510152025303540Natura&CoPfizer36.358.128.01EurofarmaHyperaPharmaGrupoNC7.556.775.945.114.98CálamoSanofiMedleyAchéNovartisBiociênciasRoche4.05427Description:In2022,Natura&CowasbyfarthelargestpharmaceuticalandcosmeticscompanyinBrazil.Thecosmeticsgroupgeneratedanetrevenueofover35billionBrazilianrealsthatyear.OtherfirmsthatmadethelistofleadingcompaniesinBrazil’spharmaceuticalandcosmeticssectorincludedPfizer,Eurofarma,HyperaPharma,andGrupoNC.ReadmoreNote(s):Brazil;2022Source(s):EditoraGlobo;ValorEconômicoLeadingpharmaceuticalcompaniesinMexicoin2023,bynetsales(inbillionMexicanpesos)MajorpharmaceuticalcompaniesinMexico2023,bynetsalesRevenueinbillionMexicanpesos15

20051025303540BayerMéxicoSanofiMéxico3716.33BoehringerIngelheimMéxicoRochéMexico14.6810.5810.27PfizerMéxicoNovartisMéxicoAstraZeneca8.718.63NovoNordisk7.316.716.525.715.33OrganonFarmacéuticosMaypoBauschHealthMéxicoEliLillydeMéxicoGlaxoSmithKline4.328Description:In2023,BayerMéxicowasthepharmaceuticalcompanywiththehighestnetsalesvalueinMexico,reachingaround37billionMexicanpesos.SanofiMéxicorankedsecond,withsalesamountingto16billionMexicanpesosthatyear.BoehringerIngelheimMéxicofollowed,witharound15billionMexicanpesos.ꢀMexico’spharmaceuticalindustryWith138pharmaceuticalmanufacturingestablishmentsoperatinginthecountry,Mexicoisthenationwiththesecondlargestpharmaceutical[...]ReadmoreNote(s):Mexico;2023Source(s):expansion.mx;VarioussourcesNetrevenueofEurofarmaLaboratóriosS.A.from2020to2023(inbillionBrazilianreals)EurofarmaLaboratóriosnetrevenueinBrazil2020-20231099.128.0187.0775.726543210202020212022202329Description:In2023,theBrazilianpharmaceuticalcompanyEurofarmaLaboratóriosS.A.generatedaconsolidatednetrevenueofapproximatelyninebillionBrazilianreals,upfromtheeightbillionrealsreportedayearbefore.Thisfigurehasbeenconstantlyincreasingsince2020,whenthecompany'snetrevenueamountedtonearlysixbillionBrazilianreals.ThemultinationalisamongtheleadingpharmaceuticalcompaniesinBrazil.ReadmoreNote(s):Brazil;2020to2023;consolidatedvaluesSource(s):Varioussources(EurofarmaLaboratórios)NetrevenuegeneratedbyGenommaLabfrom2013to2023(inbillionMexicanpesos)GenommaLab:netrevenue2013-2023181616.8216.4715.4913.871412.7112.0811.7911.541210811.3611.3211.0464202013201420152016201720182019202020212022202330Description:GenommaLabisoneoftheleadingpharmaceuticalandpersonalcarecompaniesinMexico,withahighinternationalpresence.In2023,thispharmacompanygeneratedaround16billionMexicanpesosinrevenue,upfrom11billionpesosreportedin2013.ReadmoreNote(s):Mexico;2013to2023Source(s):GenommaLabCHAPTER

05PriceandconsumptionMedicineuseinLatinAmericafrom2018to2028(inbilliondefineddailydoses)MedicationuseinLatinAmerica2018-202860050040050649648948447346144744843835734230020010002018201920202021202220232024202520262027202832Description:Anestimated461billiondefineddailydosesofmedicineswereconsumedinLatinAmericain2023.Thisfigurehasbeenincreasinginrecentyears,andisforecasttoreachover500billiondosesby2028.Bythatyear,revenueofthepharmaceuticalsmarketintheregionisforecastatapproximately56billionU.S.dollars.ReadmoreNote(s):CentralandSouthAmericaSource(s):IQVIAAveragepriceofmedicinesinselectedcountriesinLatinAmericain2022(inU.S.dollars)AveragepriceofmedicinesinLatinAmerica2022PriceinU.S.dollars2005101525303540ColombiaMexicoArgentinaChile37.729.523.921.4Brazil14.4Peru6.9Ecuador5.533Description:Accordingtoastudyconductedin2022,ColombiahadthehighestpriceofmedicinesamongsevencountriesinLatinAmerica,withanaveragepriceof37.7U.S.dollars.Mexicorankedsecond,with29.5U.S.dollars.Thatyear,BayerwastheꢀpharmaceuticalcompanywiththehighestnetsalesvalueinMexico.ReadmoreNote(s):CentralandSouthAmerica;January19

toFebruary1,2022;chronicandcommonlyusedmedications;purchasingpowerparity(Source(s):Ipsosbasedon75productsinatleastthreepharmacychainsineachcountryAveragepriceofmedicinesinselectedcountriesinLatinAmericain2022,bytypeofailment(inU.S.dollars)AveragepriceofmedicinesinLatinAmerica2022,byailmenttypePriceinU.S.dollarsAcuteChronic2505101520303540455032.732.8ColombiaChile43.11626MexicoArgentinaBrazil25.626.121.616.212.48.3Peru5.26Ecuador534Description:Accordingtoastudyconductedin2022,ColombiahadthehighestaveragepriceofmedicinesamongsevencountriesinLatinAmerica,withanaveragepriceof37.7U.S.dollars.Thatyear,Colombiaalsohadthehighestpriceofmedicationaimedatchronicdiseases,withanaverageof43.1U.S.dollars,comparedtothe32.7U.S.dollarsestimatedforacutediseases.Withinthatlastcategory,thepricewasslightlyhigherinMexico.

ReadmoreNote(s):CentralandSouthAmerica;January19

toFebruary1,2022Source(s):IpsosShareofmedicationconsumersinselectedcountriesinLatinAmericaasof2023,bycountryandpurchasechannelMedicationconsumptioninLatinAmerica2023,bypurchasechannelArgentinaBrazilChileColombiaDominicanRepublicMexicoPeru1009080706050403020100929190908887863424302928272622222120171412998888264433222222211LocalpharmacyLocalretailstoreOnlinepharmacyOnlinestoreOtherIhavenotboughtanymedicationinthelast12months35Description:Accordingtoa2023surveycarriedoutinaselectionofsixLatinAmericancountries,theleadingpurchasechannelformedicationamongrespondentsislocalpharmacies,withapproximatelynineintenintervieweeshavingpurchasedamedicationwithintheyearpriortothesurvey.Theuseoflocalretailstoresandonlineoptionssawagreatervariationbetweencountries.WhileeightpercentofBrazilianrespondentsmadeuseofretailstores,thisfigureamountedto34percentinColombia.

ReadmoreNote(s):CentralandSouthAmerica;January16toMarch18,2023;18-64yearsSource(s):SurveyNumberofusersinthee-commerceover-the-counter(OTC)pharmaceuticalsmarketinLatinAmericain2024,bysegment(inmillions)E-commerceusersofOTCpharmaceuticalsinLatinAmerica2024,bysegmentNumberofusersinmillions01020304050607080Vitamins&mineralsHandsanitizer68.6254.89Skintreatment52.14ColdandcoughremediesDigestivesandintestinalremediesIncontinence47.2241.1738.09Analgesics27.4536Description:Vitaminsandmineralsisthecategorywiththelargestnumberofusersinthee-commerceover-the-counter(OTC)pharmaceuticalsmarketinLatinAmerica,withcloseto70millionusers.Thecategoryofhandsanitizersfollows,withnearly55millionusers.Incontrast,analgesicsaccountforapproximately27millionusers.ReadmoreNote(s):Source(s):MainreasonsforconsumingsupplementsinselectedcountriesinLatinAmericain2023ReasonsforsupplementconsumptioninLatinAmerica2023Shareofrespondents30%0%10%20%40%50%60%70%EnergyboostImprovingcognitionConcentrationandfocusSleepimprovementRelaxation58%36%32%31%19%37Description:Accordingtoasurveycarriedoutamongsupplements'consumersinsixselectedLatinAmericacountries,themainreasonsforusingtheseproductsisforincreasingenergylevels.Thesecondmostcommonreasonmentionedbyintervieweeswasimprovingcognition,followedbyconcentrationandfocus.ReadmoreNote(s):CentralandSouthAmericaSource(s):GivaudanCHAPTER

06ResearchanddevelopmentMostinnovativecountriesinLatinAmericaandtheCaribbeanin2023,byglobalinnovationindexscoreGlobalinnovationindexinLatinAmericaandtheCaribbean2023,bycountryOverallGIIscore1505102025303540BrazilChile33.633.3Mexico31Uruguay3029.4ColombiaArgentinaCostaRicaPeru2827.927.7Jamaica27.1Panama25.3DominicanRepublicElSalvadorBolivia22.421.821.439Description:AccordingtotheTheGlobalInnovationIndex(GII),BrazilwasthemostinnovativecountryinLatinAmericaandtheCaribbeanin2023,withanoverallGIIscoreof33.6outof100.Mexicorankedthird,withascoreof31.ReadmoreNote(s):LAC;September2023Source(s):WIPONumberofregisteredclinicalstudiesinLatinAmericaasofApril2024,bycountryClinicalstudiesinLatinAmerica2024,bycountryNumberofstudies4,000

5,00001,0002,0003,0006,0007,0008,0009,00010,00011,000BrazilMexico9,8714,949ArgentinaChile3,9532,269ColombiaPeru1,9051,244GuatemalaPanama367352CostaRicaDominicanRepublicEcuador240231188188VenezuelaHonduras9840Description:AsofApril2024,BrazilledtherankingofLatinAmericancountrieswithmostclinicaltrials,withcloseto10,000studies.Mexicorankedsecond,withnearly5,000clinicaltrials.Brazilconcentrated4.3percentoftheclinicaltrialsperformedworldwideregardinginfectiousdiseasesin2021.ReadmoreNote(s):LAC;April17,2024Source(s):ClinicalTNumberofclinicaltrialsinitiatedinBrazilfrom2011to2021ClinicaltrialsinBrazi